Analysis of european patients enrolled in a global early access protocol with abiraterone acetate for metastatic castration-resistant prostate cancer progressing after chemotherapy
2014
Abstract
The aim of the study was to report the efficacy and safety of abiraterone acetate in a global early access protocol (EAP) in European patients. The results of this part of the EAP are consistent with the safety results of the overall EAP population and with those from the pivotal COU-AA-301 trial.